Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All DataMeds AI, Inc. filings on SEC EDGAR ↗
DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. to establish an offering program for its common stock. The company may sell shares from time to time at prevailing market prices, though it is not obligated to make any sales. The Sales Agent will receive a fixed commission of 3.0% of the gross proceeds from any shares sold.
DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) reported a net income of $10.5 million for the quarter ended September 30, 2026, primarily driven by a $19.1 million gain on debt extinguishment. However, the company experienced a significant decline in nine-month revenues from $21.7 million in 2025 to $6.0 million in 2026, resulting in a year-to-date net loss of $15.6 million.
DataMEDS AI reported Q3 2026 revenue of $2.7 million, representing 50% sequential growth driven by its Corexa Pharmacy drug dispensing business. The company achieved a net profit of $2.72 per share and regained full compliance with Nasdaq listing standards during the period. Key strategic developments included the launch of the Health Lives Here mobile app and the acquisition of the Helomics cancer diagnostics laboratory.
Term
Q3 2026
“Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions.”
DataMeds AI Deal Termination with EOS Technology Holdings, Inc.
DataMEDS AI, Inc. has terminated its Second Amended and Restated Letter of Intent (LOI) with multiple parties including EOS Technology Holdings, Scilex, and Datavault AI. The LOI contemplated the acquisition of intellectual property assets and a controlling interest in Tollo Health in exchange for common stock, but was cancelled due to market conditions. The company stated that no shares will be issued and no fees are owed as a result of the termination.
DataMeds AI M&A Deal with EOS Technology Holdings, Inc.
DataMEDS AI entered into a second amended and restated non-binding letter of intent to acquire intellectual property assets from EOS and Scilex Holding Company, and a controlling interest in Tollo Health (d/b/a Health Lives Here). The transaction involves an exchange of membership interests and the issuance of common stock that will result in the counterparties owning approximately 89.5% of the company's common stock on a fully diluted basis.
DataMeds AI, Inc. received formal notification from Nasdaq on October 19, 2026, confirming that the company has regained compliance with the $2.5 million minimum stockholders' equity requirement for continued listing. The company had previously been in deficiency since April 2026 and had also recently regained compliance with the minimum bid-price requirement in June 2026.